Ponce De Leon Health
CompanyUnited States
Ponce De Leon Health develops one asset, in phase 2 (Calcium AKG in brain aging). Mostly supplement acting on Oxidative stress and ROS signalling and epigenetic regulation of gene expression; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Alpha-ketoglutarate metabolite supplementation reducing age-related oxidative stress and supporting cellular metabolism.
Phase 2, Supplement, Oxidative stress and ROS signalling, Epigenetic regulation of gene expression, brain aging, cerebrovascular function
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals1
- Similar companies6